share_log

中國中藥：內幕消息 盈利預喜

TRAD CHI MED: INSIDE INFORMATION POSITIVE PROFIT ALERT

香港交易所 ·  Jan 28 05:14
Summary by Moomoo AI
中國中藥控股有限公司（「中國中藥」）於2024年1月28日發布內幕消息，預告其截至2023年12月31日止年度的淨利潤將同比增長85%-95%。該預喜公告指出，此一顯著的利潤增長得益於國內宏觀經濟的穩定及向好，以及公司推動經營業務增長和提質增效工作的成效。此外，公司本期的非經常性收益有所增加，而非經常性損失有所減少，進一步促進了淨利潤的增長。公司董事會提醒股東及潛在投資者在買賣公司證券時應審慎行事。
中國中藥控股有限公司（「中國中藥」）於2024年1月28日發布內幕消息，預告其截至2023年12月31日止年度的淨利潤將同比增長85%-95%。該預喜公告指出，此一顯著的利潤增長得益於國內宏觀經濟的穩定及向好，以及公司推動經營業務增長和提質增效工作的成效。此外，公司本期的非經常性收益有所增加，而非經常性損失有所減少，進一步促進了淨利潤的增長。公司董事會提醒股東及潛在投資者在買賣公司證券時應審慎行事。
CHINA PHARMACEUTICAL HOLDINGS LIMITED (“CHINA CHINESE MEDICINE”) ISSUED AN INSIDE STATEMENT ON JANUARY 28, 2024, ANNOUNCING THAT ITS NET PROFIT FOR THE YEAR ENDED DECEMBER 31, 2023 WILL GROW BY 85-95% YEAR-ON-YEAR. The announcement noted that this significant profit growth was due to the stability and direction of the domestic macro economy, as well as the company's drive for business growth and efficiency gains. In addition, the Company's non-recurring income for the period was increased, rather than reduced non-recurring losses, further contributing to the growth of net profit. The Board of Directors reminds shareholders and potential investors to exercise caution when buying and selling the Company's securities.
CHINA PHARMACEUTICAL HOLDINGS LIMITED (“CHINA CHINESE MEDICINE”) ISSUED AN INSIDE STATEMENT ON JANUARY 28, 2024, ANNOUNCING THAT ITS NET PROFIT FOR THE YEAR ENDED DECEMBER 31, 2023 WILL GROW BY 85-95% YEAR-ON-YEAR. The announcement noted that this significant profit growth was due to the stability and direction of the domestic macro economy, as well as the company's drive for business growth and efficiency gains. In addition, the Company's non-recurring income for the period was increased, rather than reduced non-recurring losses, further contributing to the growth of net profit. The Board of Directors reminds shareholders and potential investors to exercise caution when buying and selling the Company's securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more